Axsome Therapeutics stock rose 4.1% due to settlement with Teva Pharmaceuticals, positive outlook.
From Nasdaq: 2025-02-11 11:39:06
Shares of Axsome Therapeutics (NASDAQ: AXSM) rose 4.1% on Tuesday, with a peak increase of 5.6%. This surge contrasted with the S&P 500 and Nasdaq Composite’s losses of 0.3%. Mizuho raised Axsome’s price target after the company settled litigation with Teva Pharmaceuticals over patent infringement on its key drug, Auvelity. The settlement secures Axsome’s exclusive rights for approximately 14 years, prompting confidence in the company’s future. Analysts across Wall Street have revised price targets positively following the settlement, making Axsome an attractive investment option.
Axsome’s recent legal victory and positive outlook have garnered attention as the company continues to make strategic moves in the pharmaceutical industry. Mizuho’s raised price target and the settlement with Teva Pharmaceuticals have positioned Axsome as a strong player in the market, attracting potential partners and investor interest. The company’s development pipeline and upcoming phase 3 trial results add to the positive momentum surrounding Axsome, making it a stock to watch for potential growth opportunities.
Investors are advised to keep an eye on Axsome Therapeutics as it navigates through its recent legal win and positive analyst sentiment, positioning itself as a promising investment option in the pharmaceutical sector. With exclusive rights secured for its key drug, Auvelity, and potential partnerships on the horizon, Axsome’s stock performance is expected to remain robust in the near future.
Read more at Nasdaq: Why Axsome Therapeutics Stock Is Soaring Today